drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (autologous CD19-directed CAR T cell therapy)
drug_description
Autologous, gene-modified cellular therapy (CD19-directed CAR-T; relma-cel, JWCAR029) made from the patient’s T cells; administered as a single fixed dose of 1×10^8 CAR+ T cells to target and kill CD19+ B-cell lymphoma cells; expected on-target effect includes B-cell aplasia.
nci_thesaurus_concept_id
C155878
nci_thesaurus_definition
A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 and containing, as of yet undisclosed, costimulatory signaling domains, with potential immunostimulating and antineoplastic activities. Upon administration, relmacabtagene autoleucel target and bind to CD19-expressing tumor cells, thereby inducing selective toxicity in CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen expressed in all B-cell lineage malignancies.
drug_mesh_term
relmacabtagene autoleucel
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells genetically modified to express a CD19-directed chimeric antigen receptor; after infusion, the CAR binds CD19 on B cells, activating and expanding the T cells to release cytotoxic mediators and kill CD19+ lymphoma cells, with on-target B-cell aplasia.
drug_name
Relmacabtagene autoleucel
nct_id_drug_ref
NCT06479356